Skip to main content

Advertisement

SpringerLink
Log in

The combination effects of bendamustine with antimetabolites against childhood acute lymphoblastic leukemia cells

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Bendamustine combined with other drugs is clinically efficacious for some adult lymphoid malignancies, but to date there are no reports of the use of such combinatorial approaches in pediatric patients. We investigated the in vitro activity of bendamustine combined with other antimetabolite drugs on B cell precursor acute lymphoblastic leukemia (BCP-ALL) cell lines established from pediatric patients with refractory or relapsed ALL. We also developed a mathematically drown improved isobologram method to assess the data objectively. Three BCP-ALL cell lines; YCUB-2, YCUB-5, and YCUB-6, were simultaneously exposed to various concentrations of bendamustine and cladribine, cytarabine, fludarabine, or clofarabine. Cell growth inhibition was determined using the WST-8 assay. Combinatorial effects were estimated using our improved isobologram method with IC80 (drug concentration corresponding to 80 % of maximum inhibition). Bendamustine alone inhibited ALL cell growth with mean IC80 values of 11.30–18.90 μg/ml. Combinations of bendamustine with other drugs produced the following effects: (1) cladribine; synergistic-to-additive on all cell lines; (2) cytarabine; synergistic-to-additive on YCUB-5 and YCUB-6, and synergistic-to-antagonistic on YCUB-2; (3) fludarabine; additive-to-antagonistic on YCUB-5, and synergistic-to-antagonistic on YCUB-2 and YCUB-6; (4) clofarabine; additive-to-antagonistic on all cell lines. Flow cytometric analysis also showed the combination effects of bendamustine and cladribine. Bendamustine/cladribine or bendamustine/cytarabine may thus represent a promising combination for salvage treatment in childhood ALL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Tageja N, Nagi J. Bendamustine: something old, something new. Cancer Chemother Pharmacol. 2010;66:413–23.

    Article  CAS  PubMed  Google Scholar 

  2. Glode AE, Jarkowski A. Bendamustine: a new treatment option for chronic lymphocytic leukemia. Pharmacotherapy. 2009;29:1375–84.

    Article  CAS  PubMed  Google Scholar 

  3. Hagemeister F, Manoukian G. Bendamustine in the treatment of non-Hodgkin’s lymphomas. Onco Targets Ther. 2009;2:269–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Gil L, Kazmierczak M, Kroll-Balcerzak R, Komarnicki M. Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma. Med Oncol. 2014;31:944.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Fraser C, Brown P, Megason G, Ahn HS, Cho B, Kirov I, et al. Open-label bendamustine monotherapy for pediatric patients with relapsed or refractory acute leukemia: efficacy and tolerability: safety and Efficacy Outcomes. J Pediatr Hematol Oncol. 2014;36:e212–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Tageja N. Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma. Clin Med Insights Oncol. 2011;5:145–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Khouri IF, Wei W, Korbling M, Turturro F, Ahmed S, Alousi A, et al. BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. Blood. 2014;124:2306–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Schwänen C, Hecker T, Hübinger G, Wölfle M, Rittgen W, Bergmann L, et al. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia. 2002;16:2096–105.

    Article  PubMed  Google Scholar 

  9. Chow KU, Boehrer S, Napieralski S, Nowak D, Knau A, Hoelzer D, et al. In AML cell lines Ara-C combined with purine analogues is able to exert synergistic as well as antagonistic effects on proliferation, apoptosis and disruption of mitochondrial membrane potential. Leuk Lymphoma. 2003;44:165–73.

    Article  CAS  PubMed  Google Scholar 

  10. Visco C, Castegnaro S, Chieregato K, Bernardi M, Albiero E, Zanon C, et al. The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. Blood Cells Mol Dis. 2012;48:68–75.

    Article  CAS  PubMed  Google Scholar 

  11. Chow KU, Boehrer S, Geduldig K, Krapohl A, Hoelzer D, Mitrou PS, et al. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin’s lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica. 2001;86:485–93.

    CAS  PubMed  Google Scholar 

  12. Hijiya N, Thomson B, Isakoff MS, Silverman LB, Steinherz PG, Borowitz MJ, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 2011;118:6043–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Shukla N, Kobos R, Renaud T, Steinherz LJ, Steinherz PG. Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia. Pediatr Blood Cancer. 2014;61:431–5.

    Article  CAS  PubMed  Google Scholar 

  14. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys. 1979;5:85–91.

    Article  CAS  PubMed  Google Scholar 

  15. Chou TC, Talaly P. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem. 1977;252:6438–42.

    CAS  PubMed  Google Scholar 

  16. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55.

    Article  CAS  PubMed  Google Scholar 

  17. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621–81.

    Article  CAS  PubMed  Google Scholar 

  18. Chou TC. Preclinical versus clinical drug combination studies. Leuk Lymphoma. 2008;49:2059–80.

    Article  PubMed  Google Scholar 

  19. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440–6.

    Article  CAS  PubMed  Google Scholar 

  20. Goto H, Naruto T, Tanoshima R, Kato H, Yokosuka T, Yanagimachi M, et al. Chemo-sensitivity in a panel of B-cell precursor acute lymphoblastic leukemia cell lines, YCUB series, derived from children. Leuk Res. 2009;33:1386–91.

    Article  CAS  PubMed  Google Scholar 

  21. Kano Y, Ohnuma T, Okano T, Holland JF. Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture. Cancer Res. 1988;48:351–6.

    CAS  PubMed  Google Scholar 

  22. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer. 1992;50:604–10.

    Article  CAS  PubMed  Google Scholar 

  23. Kano Y, Akutsu M, Tsunoda S, Mori K, Suzuki K, Adachi KI. In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines. Cancer Chemother Pharmacol. 1998;42:91–8.

    Article  CAS  PubMed  Google Scholar 

  24. Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood. 2001;97:1999–2007.

    Article  CAS  PubMed  Google Scholar 

  25. Chacar C, Jabbour E, Ravandi F, Borthakur G, Kadia T, Estrov Z, et al. Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2012;12:197–200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Fichtner I, Arndt D, Reszka R. Antineoplastic activity and toxicity of some alkylating cytostatics (cyclophosphamide, CCNU, cytostasan) encapsulated in liposomes in different murine tumour models. J Microencapsul. 1986;3:77–87.

    Article  CAS  PubMed  Google Scholar 

  27. Carson DA, Wasson DB, Taetle R, et al. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood. 1983;62:737–43.

    CAS  PubMed  Google Scholar 

  28. Visco C, Castegnaro S, Chieregato K, Bernardi M, Albiero E, Zanon C, et al. The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. Blood Cells Mol Dis. 2012;48:68–75.

    Article  CAS  PubMed  Google Scholar 

  29. Castegnaro S, Visco C, Chieregato K, Bernardi M, Albiero E, Zanon C, et al. Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines. Leuk Lymphoma. 2012;53:2262–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hemato-Oncology and Regenerative Medicine, Kanagawa Children’s Medical Center, 2-138-4 Mutsukawa, Minami-ku, Yokohama, 232-8555, Japan

    Shoko Goto, Hiroaki Goto & Tomoko Yokosuka

Authors
  1. Shoko Goto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroaki Goto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tomoko Yokosuka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shoko Goto.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Goto, S., Goto, H. & Yokosuka, T. The combination effects of bendamustine with antimetabolites against childhood acute lymphoblastic leukemia cells. Int J Hematol 103, 572–583 (2016). https://doi.org/10.1007/s12185-016-1952-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-016-1952-z

Keywords

Search

Navigation